Potential therapeutic actions of the cannabinoids delta-9-tetrahydrocannabinol (THC) and
cannabidiol (CBD) are based on their activity as analgesics, anti-emetics, anti-inflammatory …

Background Cannabis is one of the most widely used substances worldwide. Heavy use is
associated with an increased risk of cannabis use disorders, psychotic disorders, acute …

Drug treatments available for the management of substance use disorders (SUD) present
multiple limitations in efficacy, lack of approved treatments or alarming relapse rates. These …

Recent advances in cannabidiol (CBD) use in canines and felines for anxiety management,
pain management, and anti-inflammatory effects were reviewed using a literature search …

Background The use of cannabis as medicine (CaM) both prescribed and non-prescribed
has increased markedly in the last decade, mirrored in a global shift in cannabis policy …

Cannabidiol (CBD) has become a fast-growing avenue for research in psychiatry, and
clinicians are challenged with understanding the implications of CBD for treating mental …

Rationale Cannabis-based medicinal products (CBMPs) have been identified as novel
therapeutics for generalised anxiety disorder (GAD) based on pre-clinical models; however …

Background Cannabidiol (CBD) is one of the major constituents of Cannabis sativa L. that
lacks psychotomimetic and rewarding properties and inhibits the rewarding and reinforcing …

Cannabis use peaks in adolescence, and adolescents may be more vulnerable to the neural
effects of cannabis and cannabis-related harms due to ongoing brain development during …

Abstract Background and Aims Long‐term harms of cannabis may be exacerbated in
adolescence, but little is known about the acute effects of cannabis in adolescents. We …